Gold-containing chemotherapeutic agents

Details Gold-containing chemotherapeutic agents Gold-containing chemotherapeutic agents

2006-01-24

2006-01-24

Krass, Frederick (Department: 1614)

Drug, bio-affecting and body treating compositions

Inorganic active ingredient containing

Heavy metal or compound thereof

C514S495000

Reexamination Certificate

active

06989158

ABSTRACT:
There is provided a complex for use as a therapeutic pharmaceutical, the complex has a ligand containing at least one hydroxyalkyl phosphine donor group bound to a gold atom to form a stable gold-ligand complex. Also provided is a method of treating cancer by administering an effective amount of a complex having a ligand of at least one hydroxyalkyl phosphine group bound to a gold atom to form a stable gold-ligand complex. Also provided is a method of preventing the metastasis of cancer and arresting cell growth by administering an effective amount of a complex having a ligand of at least one hydroxyalkyl phosphine group bound to a gold atom to form a stable gold-ligand complex.

REFERENCES:
patent: 5843993 (1998-12-01), Katti et al.
patent: 6183545 (2001-02-01), Okuhama et al.
patent: 2002/0006915 (2002-01-01), Strong et al.
Komiya et al, “Synthesis of water-soluble tri(hydroxymethyl)phosphine)gold(l) complexes containing a nucleoside ligand”, Inorganica Chimica Acta, vol. 217, pp. 201-202 (1994).
Chemical Abstract 127:144328, Berning et al, “Chemistry in environmentally benign media” (Sep. 2, 1997).
Berglot, F.E., et al., “Auranofin: an Oral Chrysotherapeutic Agent for the Treatment of Rheumatoid Arthritis,”J. Rheumatol., 5, 68 (1978).
Berning, D.E., et al., “In Vitro and In Vivo Characterization of a99mTc Complex with Tris(hydroxymethyl)phosphine (THP),”Hyroxymethyl bis(phosphines) and their palladium(II) and platinum(II) complexes formed via biphasic reactions. Crystal structure of [Pd(HOH2C)2PC6H4P(CH2OH)2]2]CL2Nucl. Med. Biol., 23, 617 (1996).
Fricker, S.P., “Medicinal chemistry and pharmacology of gold compounds,”Transition Met, Chem, 21, 377 (1996).
Katti, K.V., “Recent advances in the chemistry of water-soluble phosphines—Catalytic and biomedical aspects,”Curr. Sci., 70, 219 (1996).
Mirabelli, C.K., et al., “Evaluation of theIn VivoAntitumor Activity andIn VitroCytotoxic Properties of Auranofin, a Coordinated Gold Compound, in Murine Tumor Models,”Cancer Res., 45, 32 (1985).
Reddy, V.S., et al., “Chemistry in Environmentally Benign Media.”Inorg. Chem., 35, 1753 (1996).
Reddy, V.S., et al.,Inorg. Chem. Acta:, 240; 367 (1995).
Reddy, V.S., et al.,J. Chem. Soc. Dalton Trans., 1301 (1996).
Schubiger, P.A., et al., “Vehicles, Chelators, and Radionuclides: Choosing the “Building Blocks” of an Effective Therapeutic Radioimmunoconjugate,”Bioconjugate Chem., 7, 165 (1996).
Shi, J.C., et al., Chiral Phosphine Ligands Derived from Sugars.Inorg. Chem:, 35, 2742 (1996).
Simon, et al, “Screening Trial with the Coordinated Gold Compound Auranofin Using Mouse Lymphocytic Leukemia P3881,”Cancer Res., 41, 94 (1981).
Volkert, W.A., et al., “Therapeutic Radionuclides: Production and Decay Property Considerations,”J. Nucl. Med., 32, 174 (1991).

Affiliated with

Also associated with

Rating

Gold-containing chemotherapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Gold-containing chemotherapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gold-containing chemotherapeutic agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3585041